Development of a clinical marker for type-2 diabetes
Funder: AstraZeneca/Heart of England NHS TrustDuration: June 2016 - May 2017
People
| Name | Telephone | Office | ||
|---|---|---|---|---|
|
Mark Atherton
E: mark.atherton@brunel.ac.uk
|
mark.atherton@brunel.ac.uk |
Outputs
Koenig, C., Atherton, M., Cavazutti, M., Ramachandran, S., Gomm, C. and Strange, R. (2017) 'A pilot study to assess peak systolic velocity as a possible marker of atherosclerotic burden using ultrasound'.Artery 17. Pisa, Italy. 6 - 14 October. Springer Science and Business Media LLC. pp. 76 - 76. ISSN: 1872-9312 Open Access Link
Cavazzuti, M., Ramachandran, S., Koenig, C., Atherton, M., Halliday, I., Schenkel, T., et al. (2017) 'Method validation of an ultrasound (US) approach to assess velocity profile as a marker of atherosclerotic burden'.MEIBioeng/MPEC2017. Sandown Racecourse, Esher, Surrey.Open Access Link
König, C., Ramachandran, S., Cavazzuti, M., Atherton, M. and Gomm, C. (2017) 'Method validation of an ultrasound (US) approach to assess velocity profile as a marker of atherosclerotic burden'.AstraZeneca CVMD Research Summit 2017. Rome, Italy.